問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

陳浤燿Chen, Hung-Yao
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • D13460@mail.cmuh.org.tw

Recruiting Trial

17Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳浤燿

List

43Cases

2014-12-01 - 2016-12-31

Others

A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region

  • Condition/Disease

    chronic Hepatitis B

  • Test Drug

    ABX203

Participate Sites
12Sites

Terminated12Sites

2015-10-26 - 2017-05-30

Phase III

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 1 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
9Sites

Terminated8Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2015-09-16 - 2017-06-30

Phase III

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Condition/Disease

    Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Test Drug

    ABT-450/Ritonavir/ABT-267, ABT-333, Ribavirin

Participate Sites
6Sites

Terminated5Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2015-10-20 - 2017-05-30

Phase III

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 2 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
7Sites

Terminated4Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2017-04-01 - 2018-12-31

Phase III

A Single Arm, Open-label Study to Evaluatehe Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naive Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2,4, 5 or 6Infection and Compensated Cirrhosis

  • Condition/Disease

    Chronic Hepatitis C Virus (HCV)

  • Test Drug

    Glecaprevir、Pibrentasvir

Participate Sites
4Sites

Terminated3Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2020-05-01 - 2025-03-31

Phase II

A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    RO7049389、RO7020531、Vemlidy韋立得、Viread 惠立妥、Baraclude 貝樂克

Participate Sites
6Sites

Recruiting6Sites

2020-05-01 - 2024-11-18

Phase I/II

Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infection

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Chimpanzee adenovirus HBV vaccine, 2.Modified Vaccinia Ankara HBV vaccine, 3.HBc-HBs/AS01_B4,

Participate Sites
5Sites

Recruiting5Sites

2015-09-01 - 2016-08-31

Others

STUDY TO EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS OF ASC16 (RAVIDASVIR) IN COMBINATION WITH RITONAVIR-BOOSTED ASC08 (DANOPREVIR) AND RIBAVIRIN IN TREATMENT-NAIVE NON-CIRRHOTIC TAIWANESE PATIENTS WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1.

  • Condition/Disease

    Chronic Hepatitis C Genotype 1

  • Test Drug

    ASC16 & ASC08

Participate Sites
5Sites

Terminated5Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2017-02-01 - 2019-06-30

Others

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

  • Condition/Disease

    The plan includes adult male and female CHB subjects aged 18 to 70 (inclusive) who are not currently receiving CHB treatment. Part 1 (Groups A, B, C, and D) will include HBeAg-positive subjects, while Part 1 (Group C1) will include HBeAg-negative subjects. After completing part 1 of the administration (after reviewing the safety, tolerability, PK and PD differences between HBeAg status), the specific CHB group included in part 2 will be determined

  • Test Drug

    GSK3389404

Participate Sites
9Sites

Recruiting8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB